About Us

We’re a Canadian health supplements company dedicated to protect, restore and regain a healthier body and mind through the production and distribution of artisanal, medicinal mushrooms.

Our Vision

Humanity has relied on the extraordinary healing powers of mushrooms for thousands of years. Their organic biochemical structure is adapted to treat many of our modern conditions. Whether stress or anxiety, muscular pain, or insomnia, mushrooms have been shown to nourish and restore our minds and bodies, reintroducing balance and harmony

We are dedicated to researching and developing new ways of distilling and purifying mushrooms in order to harness their healing properties in order to nurture healthier, happier lives.

Our Ethos

Psyched Wellness was created with the purpose of benefitting the health of people, plants and the planet. Our business model is built on an ethos of regenerating our environment and society. Inspired by sustainability, our products are organically farmed and Fair Trade.

MEET THE TEAM

Jeff Stevens

CEO & Director

Mr. Stevens has 20+ years of capital markets experience and has been an officer and director with several public companies.

He has taken three companies public via reverse takeover, built teams and structured multiple M&A transactions while building successful businesses.

Read Bio >>

David Shisel

COO

The Company’s Chief Operating Officer, has experience in highly regulated industries such as medical cannabis and has previously worked in legal capacities with various licensed producers. He also has expertise in product development, working with GMP manufacturers to identify product manufacturing requirements and establishing operations for pharmaceutical companies.

Read Bio >>

Michael Nederhoff

Chairman

Currently acts as President of JUUL Labs in Canada overseeing Canadian operations including product launches, organizational structure and P&L responsibility.

Previously served as GM for CytoSport, Inc. overseeing the Canadian launch of Muscle Milk and was one of the first 10 employees at Red Bull Canada where he held senior sales roles for 8+ years.

Read Bio >>

Nick Kadysh

Director

Head of Corporate Affairs at JUUL Labs Canada. Formerly served as Government Affairs & Public Leader at GE Healthcare and Director of Public Affairs for Red Bull Canada.

Following a career as a political advisor, Nick specializes in managing regulatory risk for companies in the food and drug industry.

Read Bio >>

Terry Booth

Director

one of the Company’s directors co-founded Aurora Cannabis Inc. in 2013 when the Canadian federal government created a new regulatory regime for the national medical cannabis system. He brings insight and relationships to the Company, which will be important in establishing future manufacturing operations, as well as securing relationships to market the Company’s products.

Read Bio >>

Professor David Nutt

Director

David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Imperial College London. He was previously President of the, European Brain Council, British Association of Psychopharmacology, British Neuroscience Association and European College of Neuropsychopharmacology. He is currently Founding Chair of DrugScience.org.uk and holds visiting Professorships at the Open University and University of Maastricht. In 2013 he won the John Maddox Prize from Nature/Sense about Science for standing up for science and in 2017 a Doctor of Laws hon causa from the University of Bath.
Professor Nutt currently sits as the Chair of the Scientific Advisory Board for COMPASS Pathways and Chair of the Scientific Advisory Board for AWAKN Life Sciences. He is also a member of the Medical Advisory Board of Opiant and sits on the board of Lundbeck Institute Campus.

1. Psilocybin for treatment-resist ant depression: a feasibility study Lancet Psychiatry epub May 18th

2. Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression

3. Psychedelic Psychiatry's Brave New World

4. The Current Status of Psychedelics in Psychiatry

Read Bio >>

Advisory board

Dr. Dawn DeCunha

Advisor

Dr. Dawn DeCunha is a clinical psychologist, with an active practice in Toronto, Canada. She is a member of the College of Psychologists of Ontario and the Canadian Register of Health Service Psychologists. She is the founder and clinical director of Psychology Works, a community based clinic providing psychological assessment and treatment to a wide variety of patients ranging in age from young children to seniors. After more than two decades of trauma informed practice, which has included extensive work in Family, Civil and Criminal Court, Dr. DeCunha has turned her focused attention to the most promising area of research in mental health in the history of psychology: Psychedelic Assisted Research and Therapy.

Dr. Andrew Kohler

Advisor

Dr. Kohler is the founder and owner of Callingwood Crossing Medical Center, which he has built over the years through a series of acquisitions. He is actively involved raising money for Edmonton based health and education initiatives and also works part time teaching medical students as a Clinical Professor of Medicine from the University of Alberta School of Medicine and Dentistry. Mr. Kohler participated in various pharmaceutical trials and studies. Mr. Kohler is an associate clinical professor of medicine at the University of Alberta.

Kevin Feeney, PhD, JD

Advisor

Kevin Feeney, PhD, JD, is a cultural anthropologist and lawyer currently working as a Program Director and Instructor in Interdisciplinary Studies – Social Sciences at Central Washington University. His primary research interests include examining legal and regulatory issues surrounding the religious and cultural use of psychoactive substances, with an emphasis on peyote and ayahuasca, and exploring modern and traditional uses of Amanita muscaria, with a specific focus on medicinal use and preparation practices. He has recently published an edited volume on Amanita muscaria (Fly Agaric: A Compendium of History, Pharmacology, Mythology, and Exploration) and has also been published in the International Journal of Drug Policy, Journal of Psychoactive Drugs, Human Organization, and Curare, among other books and journals (Research articles and other writings can be found at: https://www.researchgate.net/profile/Kevin_Feeney). 

View Book

Aaron Slater

Advisor

Aaron Slater has over twenty-five years of experience in Corporate Finance, M&A and Merchant Banking. He has been involved in over US$8 billion in transactions including a number of buy-out deals in Latin America, USA and Canada following from which he continues to maintain his involvement through being a director or shareholder. Currently, Aaron is a shareholder and executive director of one of the largest organic farms in Latina America. Aaron has worked with various High Net Worth Individuals, Family Offices and Hedge Funds to provide them a private equity capability that includes deal sourcing, structuring, investment oversight and managing liquidity events. These efforts have resulted in numerous successful investments with a specific focus on agriculture, natural resources and sustainability.

Aaron was head of Corporate Finance in the Americas for Standard Bank Group focusing primarily in middle market companies. Prior to that he was with Royal Bank of Canada where he implemented and established a corporate finance and M&A product line for the private banking client base throughout the United States, Latin America and the Caribbean. Previous to that Aaron was part of NationsBanc Montgomery Securities Investment Banking Group.

Aaron holds a B.A. in Political Science from the University of Western Ontario and an M.A. in International Relations from the University of Miami.